Transplant center directory

The University of Michigan’s BMT program averages 250 transplants each year-making us one of the largest programs in the state of Michigan. Our program is patient-focused, research-driven and internationally recognized for expertise in transplantation. Our Adult & Pediatric program has maintained FACT accreditation for the past 20 years and maintains a multidisciplinary approach to treating our BMT patients. Our medical teams are comprised of physician, nurse coordinators, physician assistants, social work, and pharmacists working together with insurance and financial teams to provide each patient the best care all in one hospital. In addition, we also have one of the best Extra Corporeal Photopheresis (ECP) programs in the state of Michigan that provides cutting-edge therapies to transplant patients with graft-vs.-host disease (GVHD).

This center has been performing allogeneic transplants since 1990 and has been an NMDP/Be The Match transplant center since September 1994.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 311 patients.

The actual 1-year survival of these patients is 74.8%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 72.2% and 81.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.